Media

The Biotechnology Innovation Organization (BIO) is pleased to announce that the Honorable Dennis McGinn, Assistant Secretary of the Navy, Energy, Installations...
BIO Executive Vice President for Health Policy Dan Durham released the following statement regarding yesterday’s proposed Part B Drug Payment Model and...

Press Releases

Feb 2 2004
WASHINGTON, D.C. (February 2, 2004) - Biotechnology Industry Organization (BIO) President Carl B. Feldbaum and BIO Chairman Richard Pops today issued the...
Jan 28 2004
WASHINGTON, D.C. (January 28, 2004) — The opening plenary session at the BIO CEO & Investor Conference will focus on different approaches to sustaining...
Jan 22 2004
Dr. Val Giddings, vice president of agriculture for the Biotechnology Industry Organization (BIO) issued the following statement in response to today's...
Jan 21 2004
U.S. Department of CommerceUnited States-Israel BioRoundtable Seminar Series January 26, 2004 Introductory Remarks by Under Secretary Phillip Bond Featured...
Jan 20 2004
Dr. Val Giddings, vice president of agriculture of the Biotechnology Industry Organization (BIO) issued the following statement in response to today's National...
Jan 13 2004
WASHINGTON (January 13, 2004) – Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), issued the following statement in response to a...
Jan 8 2004
WASHINGTON, D.C. (January 8, 2004) — Representatives from the biotechnology, chemical and agriculture industries will join with government officials and...
Jan 7 2004
WASHINGTON, D.C. (January 7, 2004) - The Biotechnology Industry Organization (BIO) today announced that Elias Zerhouni, M.D., director of the National...
Jan 5 2004
WASHINGTON, D.C. (January 5, 2004) — The biotechnology industry enters 2004 stronger than ever after earning 37 FDA approvals, raising $16.4 billion in new...


Biotechnology News

Feb 8 2016 - 12:27pm
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s announced today that its US subsidiary, Promius PharmaTM, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), has received approval for Sernivo™ (betamethasone dipropionate) Spray, 0.05% from the U.S. Food and Drug Administration (FDA). Sernivo Spray, a prescription topical steroid, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. The commercial launch of the product is planne

Feb 8 2016 - 12:27pm
LONDON--(BUSINESS WIRE)--AstraZeneca and MedImmune, its global biologics research and development arm, today announced publication in The Lancet Oncology of a Phase Ib study (study 006), showing antitumour activity of combination treatment with durvalumab and tremelimumab, in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 status.1 In a cohort of 26 patients treated with durvalumab 10-20 mg/kg plus tremelimumab 1 mg/kg, and followed for ≥24

Feb 8 2016 - 12:27pm
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News: STENTYS (FR0010949404 — STNT – éligible PEA PME) (Paris:STNT), société de technologie médicale qui commercialise le premier et le seul stent auto-apposant coronaire, annonce ce jour les premiers accords de distribution de son stent actif pour le traitement des artères sous le genou (BTK – below-the-knee) en Allemagne et en Belgique, ce qui en fait le premier stent actif auto-expansif commercialisé dans cette indication en Europe. Le ste

Feb 8 2016 - 12:27pm
PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--Regulatory News: STENTYS (FR0010949404 — STNT) (Paris:STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces the first distribution agreements for its drug-eluting stent for treating BTK (Below-The Knee) arteries in Germany and Belgium, making it the first self-expanding drug-eluting stent commercialized for this indication in Europe. The STENTYS stent obtained CE Marking for the BTK

Feb 8 2016 - 12:27pm
LONDRES--(BUSINESS WIRE)--AstraZeneca et MedImmune, sa branche internationale de recherche et de développement de produits biologiques, ont annoncé aujourd’hui la publication dansThe Lancet Oncology d’une étude de Phase Ib (Étude 006), qui indique une activité antitumorale de la thérapie combinée, associant le durvalumab et le tremelimumab, chez les patients qui souffrent d’un cancer bronchique non à petites cellules (CBNPC), localement avancé ou métastatique, indifféremment du statut PD-L1.1 P

Feb 8 2016 - 12:27pm
LONDON--(BUSINESS WIRE)--AstraZeneca und MedImmune, sein globaler Forschungs- und Entwicklungszweig für Biologika, meldeten heute die Veröffentlichung einer Phase-Ib-Studie (Studie 006) in der Fachzeitschrift The Lancet Oncology , in der eine tumorhemmende Wirkung der Kombinationstherapie mit Durvalumab plus Tremelimumab bei Patienten mit lokal fortgeschrittenem oder metastasierendem, nicht-kleinzelligem Lungenkrebs (NSCLC) nachgewiesen wurde, und zwar unabhängig vom PD-L1-Status.11 In einer Ko

Feb 8 2016 - 12:27pm
LONDRES--(BUSINESS WIRE)--A AstraZeneca e a MedImmune, seu braço global de desenvolvimento e pesquisa biológica, anunciou hoje a publicação na The Lancet Oncology de um estudo da Fase Ib (estudo 006) mostrando a atividade antitumoral do tratamento combinado com durvalumab e tremelimumabe em pacientes com câncer no pulmão de não pequenas células (NSCLC) localmente avançado ou metastático, independentemente do seu estado de PD-L1.1 Em uma coorte de 26 pacientes tratados com de durvalumab 10-20 mg

Feb 8 2016 - 12:27pm
LONDRA--(BUSINESS WIRE)--AstraZeneca e MedImmune, la sua branca di ricerca biologica e di sviluppo globale, hanno annunciato oggi la pubblicazione in The Lancet Oncology di uno studio di fase Ib (studio 006) che dimostra l'attività antitumorale del trattamento combinato di durvalumab e tremelimumab in pazienti con tumore ai polmoni non di piccole cellule localmente avanzato o metastatico (NSCLC), indipendentemente dallo stato del PD-L1. Il testo originale del presente annuncio, redatto nella li

Feb 8 2016 - 12:27pm
LONDRES--(BUSINESS WIRE)--AstraZeneca y MedImmune, su división global de investigación y desarrollo en medicamentos biológicos, anunció hoy la publicación en The Lancet Oncology de un estudio de Fase Ib (estudio 006), que muestra la actividad antitumoral del tratamiento de combinación de durvalumab y tremelimumab, en pacientes con cáncer de pulmón no microcítico avanzado localmente o metastásico (NSCLC), independientemente de la condición de PD-L1.1 En un cohorte de 26 pacientes tratados con du

Feb 8 2016 - 12:27pm
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext : IMPL, FR0010458729, éligible PEA-PME), société de technologies médicales spécialisée dans les implants rachidiens et les implants de chirurgies du genou, annonce la nomination de Brian T. Ennis au poste de Président de Implanet America. À ce titre, il prend la direction de Implanet America et a pour objectif d’optimiser sa structure organisationnelle afin d’accélérer l’adoption et la progression de la technologie